{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:10:33Z","timestamp":1783476633548,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.thromres.2021.02.005","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T09:43:53Z","timestamp":1612863833000},"page":"149-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Effects of antithrombotic drugs on the prothrombotic state in patients with atrial fibrillation: The west Birmingham atrial fibrillation project"],"prefix":"10.1016","volume":"200","author":[{"given":"Christos","family":"Voukalis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Shantsila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.thromres.2021.02.005_bb0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cvr\/cvy272","article-title":"The prothrombotic state in atrial fibrillation: pathophysiological and management implications","volume":"115","author":"Khan","year":"2019","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.thromres.2021.02.005_bb0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1161\/CIRCULATIONAHA.110.952648","article-title":"Thrombin generation in hemorrhage control and vascular occlusion","volume":"124","author":"Mann","year":"2011","journal-title":"Circulation."},{"issue":"12","key":"10.1016\/j.thromres.2021.02.005_bb0015","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann. Intern. Med."},{"issue":"11","key":"10.1016\/j.thromres.2021.02.005_bb0020","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2021.02.005_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205989","article-title":"Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban","volume":"13","author":"Tepper","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.thromres.2021.02.005_bb0030","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/ATVBAHA.117.308564","article-title":"Fibrinogen and fibrin in hemostasis and thrombosis","volume":"37","author":"Kattula","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.thromres.2021.02.005_bb0035","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2141.2010.08546.x","article-title":"Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate*","volume":"152","author":"Blomb\u00e4ck","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.thromres.2021.02.005_bb0040","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1053\/euhj.1998.1088","article-title":"Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid","volume":"19","author":"Williams","year":"1998","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.thromres.2021.02.005_bb0045","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjh.12975","article-title":"Measurement of non-Coumarin anticoagulants and their effects on tests of Haemostasis: guidance from the British Committee for Standards in Haematology","volume":"166","author":"Kitchen","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.thromres.2021.02.005_bb0050","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2257.2005.00681.x","article-title":"Thrombelastography\/thromboelastometry","volume":"27","author":"Luddington","year":"2005","journal-title":"Clin. Lab. Haematol."},{"key":"10.1016\/j.thromres.2021.02.005_bb0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.vph.2015.02.013","article-title":"Development and validation of a new assay for assessing clot integrity","volume":"71","author":"Ranjit","year":"2015","journal-title":"Vasc. Pharmacol."},{"issue":"5","key":"10.1016\/j.thromres.2021.02.005_bb0060","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/jth.14002","article-title":"An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH","volume":"16","author":"Pieters","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2021.02.005_bb0065","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2141.1965.tb06586.x","article-title":"The kaolin clotting time of platelet-rich plasma: a test of platelet Factor-3 availability","volume":"11","author":"Hardisty","year":"1965","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.thromres.2021.02.005_bb0070","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.atherosclerosis.2007.05.028","article-title":"Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress","volume":"196","author":"Undas","year":"2008","journal-title":"Atherosclerosis."},{"issue":"2","key":"10.1016\/j.thromres.2021.02.005_bb0075","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11239-016-1344-5","article-title":"Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis","volume":"42","author":"Lau","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2021.02.005_bb0080","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/jth.12229","article-title":"Fibrin(ogen) and thrombotic disease","volume":"11","author":"Ari\u00ebns","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"15","key":"10.1016\/j.thromres.2021.02.005_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7150","article-title":"Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation","volume":"7","author":"Boland","year":"2003","journal-title":"Health Technol. Assess."},{"issue":"8","key":"10.1016\/j.thromres.2021.02.005_bb0090","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1111\/j.1538-7836.2005.01420.x","article-title":"PAI-1 and atherothrombosis","volume":"3","author":"Vaughan","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2021.02.005_bb0095","article-title":"Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis","volume":"87","author":"Weitz","year":"1991"},{"issue":"1","key":"10.1016\/j.thromres.2021.02.005_bb0100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1152\/physrev.00016.2011","article-title":"New fundamentals in hemostasis","volume":"93","author":"Versteeg","year":"2013","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.thromres.2021.02.005_bb0105","doi-asserted-by":"crossref","unstructured":"Voukalis C, Shantsila E, Lip GYH. Microparticles and cardiovascular diseases. Ann Med. 2019;51(3\u20134).","DOI":"10.1080\/07853890.2019.1609076"},{"issue":"8","key":"10.1016\/j.thromres.2021.02.005_bb0110","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1177\/1076029618790092","article-title":"Role of Thromboelastography and rotational thromboelastometry in the management of cardiovascular diseases","volume":"24","author":"Korpallov\u00e1","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"1","key":"10.1016\/j.thromres.2021.02.005_bb0115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.transci.2007.12.005","article-title":"Thrombin generation, fibrin clot formation and hemostasis","volume":"38","author":"Wolberg","year":"2008","journal-title":"Transfus. Apher. Sci."},{"issue":"2","key":"10.1016\/j.thromres.2021.02.005_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171486","article-title":"Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: studies with circulating blood and in a platelet-based model of thrombin generation","volume":"12","author":"Pujadas-Mestres","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.thromres.2021.02.005_bb0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1055\/s-0039-1698460","article-title":"Interpretation and validation of maximum absorbance data obtained from turbidimetry analysis of plasma clots","volume":"120","author":"Pieters","year":"2020","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2021.02.005_bb0130","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ijlh.12688","article-title":"Global assays of fibrinolysis","volume":"39","author":"Ilich","year":"2017","journal-title":"Int. J. Lab. Hematol."},{"issue":"12","key":"10.1016\/j.thromres.2021.02.005_bb0135","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1161\/ATVBAHA.111.230631","article-title":"Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases","volume":"31","author":"Undas","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.thromres.2021.02.005_bb0140","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1161\/ATVBAHA.110.213389","article-title":"Molecular mechanisms affecting fibrin structure and stability","volume":"31","author":"Lord","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.thromres.2021.02.005_bb0145","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/ndt\/gfm884","article-title":"Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality","volume":"23","author":"Undas","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"issue":"46","key":"10.1016\/j.thromres.2021.02.005_bb0150","first-page":"3258","article-title":"Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors","volume":"36","author":"Lip","year":"2015","journal-title":"Eur. Heart J."},{"issue":"16","key":"10.1016\/j.thromres.2021.02.005_bb0155","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.thromres.2021.02.005_bb0160","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s11239-018-1641-2","article-title":"Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications","volume":"45","author":"Gorog","year":"2018","journal-title":"J. Thromb. Thrombolysis"},{"issue":"2","key":"10.1016\/j.thromres.2021.02.005_bb0165","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.atherosclerosis.2010.12.040","article-title":"Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans","volume":"215","author":"Undas","year":"2011","journal-title":"Atherosclerosis."},{"issue":"2","key":"10.1016\/j.thromres.2021.02.005_bb0170","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1055\/s-0038-1656337","article-title":"Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis","volume":"68","author":"Fatah","year":"1992","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2021.02.005_bb0175","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1055\/s-0038-1650618","article-title":"Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age","volume":"76","author":"Fatah","year":"1996","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2021.02.005_bb0180","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1681\/ASN.2016030336","article-title":"Clot structure: a potent mortality risk factor in patients on hemodialysis","volume":"28","author":"Schuett","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.thromres.2021.02.005_bb0185","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-2141.2008.07568.x","article-title":"Hypofibrinolysis is a risk factor for arterial thrombosis at young age","volume":"145","author":"Guimar\u00e3es","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2021.02.005_bb0190","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood-2010-02-267740","article-title":"Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1","volume":"116","author":"Meltzer","year":"2010","journal-title":"Blood."},{"issue":"05","key":"10.1016\/j.thromres.2021.02.005_bb0195","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1055\/s-0037-1615530","article-title":"D-dimer and factor VIIa in atrial fibrillation \u2013 prognostic values for cardiovascular events and effects of anticoagulation therapy","volume":"115","author":"Siegbahn","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2021.02.005_bb0200","first-page":"632","article-title":"Determinants of tPA antigen and associations with coronary artery disease and acute cerebrovascular disease","volume":"80","author":"Carter","year":"1998","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2021.02.005_bb0205","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11239-014-1101-6","article-title":"D-dimer elevation and adverse outcomes","volume":"39","author":"Halaby","year":"2015","journal-title":"J. Thromb. Thrombolysis"},{"issue":"2","key":"10.1016\/j.thromres.2021.02.005_bb0210","first-page":"120","article-title":"Risk factors for venous and arterial thrombosis","volume":"9","author":"Previtali","year":"2011","journal-title":"Blood Transfus."},{"issue":"18","key":"10.1016\/j.thromres.2021.02.005_bb0215","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.jacc.2007.11.083","article-title":"Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction","volume":"51","author":"Akar","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"07","key":"10.1016\/j.thromres.2021.02.005_bb0220","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1160\/TH09-12-0837","article-title":"Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients","volume":"104","author":"Kaireviciute","year":"2010","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2021.02.005_bb0225","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1161\/CIRCRESAHA.110.233163","article-title":"Microparticles, vascular function, and atherothrombosis","volume":"109","author":"Rautou","year":"2011","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.thromres.2021.02.005_bb0230","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12959-018-0166-4","article-title":"Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis","volume":"16","author":"Jung","year":"2018","journal-title":"Thromb. J."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384821000529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384821000529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:45:56Z","timestamp":1758735956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384821000529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":46,"alternative-id":["S0049384821000529"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2021.02.005","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of antithrombotic drugs on the prothrombotic state in patients with atrial fibrillation: The west Birmingham atrial fibrillation project","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2021.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}